LIVER STIFFNESS METHODS IN CHILDREN WITH OBESITY USING SHEAR WAVE ELASTOGRAPHY
Abstract
Resume: This original article presents data on the study of liver parenchymal stiffness using elastography in obese and normal-weight children. The obtained results can be incorporated into the practice of pediatricians and pediatric gastroenterologists. Objective: To evaluate the diagnostic efficacy of liver ultrasound elastography in patients with obesity and non-alcoholic fatty liver disease (NAFLD). Materials and Methods: Sixty-eight children with obesity and non-alcoholic fatty liver disease were studied. All children underwent liver parenchymal stiffness testing using the Fibroscan device. Study results: These results have significant prognostic value and confirm the pathogenetic role of NAFLD in the development of fibrotic liver changes in children with visceral obesity associated with impaired carbohydrate and lipid metabolism. Elevated ALT activity reflects impaired liver metabolism and is accompanied by the development of liver inflammation induced by hyperleptinemia and leptin resistance. Conclusions: The combination of metabolic disturbances associated with inflammation in children with visceral obesity contributes to the progression of liver steatosis and the development of fibrosis, which creates the preconditions for the subsequent development of steatohepatitis.
Keywords:
About the Authors
List of references
Shirokova E.N. et al. Elastography in the diagnosis of non-alcoholic fatty liver disease. Vestnik RAMS. 2019. - (74)1:-5–13.
Serkova M.Yu., Skvortsova T.E., Bakulin I.G. Diagnostic capabilities of the elastography method and shear wave steatometry in patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020-(12):49–52.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004.
Byrne C, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi: 10.1016/j.jhep.2014.12.012.
Putri RR, Casswall T, Danielsson P, Marcus C, Hagman E. Steatotic liver disease in pediatric obesity and increased risk for youth-onset type 2 diabetes. Diabetes Care 2024. https://doi.org/10.2337/dc24-1236.
Kehar M, Ibrahim SH, Ramirez CM, Amin SA, Diamond T, Mohammad S. Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease. J Pediatr Gastroenterol Nutr 2024; 79(3):661–6. https://doi.org/10.1002/jpn3.12236.
World Health Organization. WHO Child growth standards: Methods and development. Geneva: WHO; 2017
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.